ABIVAX (ABVX) Appoints Michael Nesrallah as Chief Commercial Officer

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 2, 2026, ABIVAX Société Anonyme (NASDAQ:ABVX) appointed Michael Nesrallah as chief commercial officer. Michael Nesrallah will lead global commercial strategy and launch preparation for obefazimod as the company moves toward potential regulatory approval, bringing more than 20 years of biopharmaceutical experience, including prior senior leadership roles at Takeda.

On March 24, 2026, Barclays raised the price target on ABIVAX Société Anonyme (NASDAQ:ABVX) to $148 from $142 and maintained an Overweight rating. Barclays said a “clean” Data and Safety Monitoring Board review supports continued ABTECT maintenance, with a readout expected in late Q2.

ABIVAX (ABVX) Appoints Michael Nesrallah as Chief Commercial Officer

Photo by RephiLe water on Unsplash

On March 15, 2026, Jefferies initiated coverage on ABIVAX Société Anonyme (NASDAQ:ABVX) with a Buy rating and a $160 price target. Jefferies described obefazimod as a “differentiated” treatment for ulcerative colitis and said the upcoming Q2 maintenance readout appears “fairly de-risked,” while also pointing to potential in Crohn’s disease.

ABIVAX Société Anonyme (NASDAQ:ABVX) develops therapeutics targeting chronic inflammatory diseases.

While we acknowledge the risk and potential of ABVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABVX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.